Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics (Nasdaq: OVID) said management will present at three investor conferences between Feb 25 and Mar 11, 2026, with scheduled times listed for each event.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ovid Therapeutics (Nasdaq: OVID) said management will present at three investor conferences between Feb 25 and Mar 11, 2026, with scheduled times listed for each event.
A live webcast will be available at the company’s Events & Presentations page and an archived replay will be posted for about 30 days.
Details
News Market Reaction – OVID
On Feb 25, the day this news came out, OVID closed 7.28% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced that the Company’s management will participate in three upcoming investor conferences:
- Oppenheimer 36th Annual Healthcare Life Sciences Conference – Wednesday, February 25th at 11:20 am ET
- 46th Annual TD Cowen Health Care Conference – Wednesday, March 4th at 9:50 am ET
- Leerink Partners Global Healthcare Conference 2026 – Wednesday, March 11th at 3:00 pm ET
A live webcast of the presentations can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 30 days.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions and symptoms caused by excess neural excitability. Ovid is advancing a pipeline of novel targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; and is developing OV4071 and other candidates within a library of compounds that directly activate the KCC2 transporter for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Contact
Investor Relations & Media
Victoria Fort
VFort@ovidrx.com
202.361.0445
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.